Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.85) by 62.95 percent. This is a 247.5 percent decrease over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $947.000 thousand which beat the analyst consensus estimate of $94.667 thousand by 900.35 percent. This is a 224.77 percent increase over sales of $(759.000 thousand) the same period last year.